fda compounding semaglutide warning 2025 october New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Issues Warning: Compounding Certain

Choosing the Right Incretin Agent Once a liverfirst patient is identified, the next step is selecting the most appropriate incretin agent

The increases are generally temporary and vary between individuals, but they are one reason GHRP-2 is considered less selective than newer growth hormone secretagogues such as Ipamorelin, which tend to have minimal effects on cortisol and prolactin

Side effects are broadly similar to semaglutide (nausea, constipation, or headache in the early weeks), with one addition specific to tirzepatide some people notice a mild reaction at the injection site

The Buzz Around Choline Do you want to optimize your liver function

23:S265